Abstract

Since its discovery, polycythemia vera (PV) has challenged clinicians responsible for its diagnosis and management and scientists investigating its pathogenesis. As a clonal hematopoietic stem cell (HSC) disorder, PV is a neoplasm but its driver mutations result in overproduction of morphologically and functionally normal blood cells. PV arises in an HSC but it can present initially as isolated erythrocytosis, leukocytosis, thrombocytosis, or any combination of these together with splenomegaly or myelofibrosis, and it can take years for a true panmyelopathy to appear. PV shares the same JAK2 mutation as essential thrombocytosis and primary myelofibrosis, but erythrocytosis only occurs in PV. However, unlike secondary causes of erythrocytosis, in PV, the plasma volume is frequently expanded, masking the erythrocytosis and making diagnosis difficult if this essential fact is ignored. PV is not a monolithic disorder: female patients deregulate fewer genes and clinically behave differently than their male counterparts, while some PV patients are genetically predisposed to an aggressive clinical course. Nevertheless, based on what we have learned over the past century, most PV patients can lead long and productive lives. In this review, using clinical examples, I describe how I diagnose and manage PV in an evidence-based manner without relying on chemotherapy.

REFERENCES

REFERENCES
1.
Osler
W
.
A clinical lecture on erythremia
.
Lancet
.
1908
;
171
(
1
):
143
-
146
.
2.
Vannucchi
AM
.
How I treat polycythemia vera
.
Blood
.
2014
;
124
(
22
):
3212
-
3220
.
3.
Spivak
JL
,
Silver
RT
.
The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal
.
Blood
.
2008
;
112
(
2
):
231
-
239
.
4.
Arber
DA
,
Orazi
A
,
Hasserjian
R
, et al
.
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
.
Blood
.
2016
;
127
(
20
):
2391
-
2405
.
5.
Beer
PA
,
Erber
WN
,
Campbell
PJ
,
Green
AR
.
How I treat essential thrombocythemia
.
Blood
.
2011
;
117
(
5
):
1472
-
1482
.
6.
Rumi
E
,
Cazzola
M
.
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms
.
Blood
.
2017
;
129
(
6
):
680
-
692
.
7.
Catani
L
,
Zini
R
,
Sollazzo
D
, et al
.
Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia
.
Leukemia
.
2009
;
23
(
5
):
997
-
1000
.
8.
Spivak
JL
,
Considine
M
,
Williams
DM
, et al
.
Two clinical phenotypes in polycythemia vera
.
N Engl J Med
.
2014
;
371
(
9
):
808
-
817
.
9.
Berk
PD
,
Goldberg
JD
,
Donovan
PB
,
Fruchtman
SM
,
Berlin
NI
,
Wasserman
LR
.
Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols
.
Semin Hematol
.
1986
;
23
(
2
):
132
-
143
.
10.
Spivak
JL
.
Polycythaemia vera and precision medicine: a prescription for the 21st century
.
Lancet Oncol
.
2017
;
18
(
1
):
9
-
11
.
11.
Spivak
JL
.
Polycythemia vera: myths, mechanisms, and management
.
Blood
.
2002
;
100
(
13
):
4272
-
4290
.
12.
Spivak
JL
.
Myeloproliferative neoplasms
.
N Engl J Med
.
2017
;
376
(
22
):
2168
-
2181
.
13.
Yamamoto
R
,
Morita
Y
,
Ooehara
J
, et al
.
Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells
.
Cell
.
2013
;
154
(
5
):
1112
-
1126
.
14.
Dameshek
W
.
Physiopathology and course of polycythemia vera as related to therapy
.
J Am Med Assoc
.
1950
;
142
(
11
):
790
-
797
.
15.
Wasserman
LR
.
The management of polycythaemia vera
.
Br J Haematol
.
1971
;
21
(
4
):
371
-
376
.
16.
Stein
BL
,
Williams
DM
,
Wang
NY
, et al
.
Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders
.
Haematologica
.
2010
;
95
(
7
):
1090
-
1097
.
17.
Senín
A
,
Fernández-Rodríguez
C
,
Bellosillo
B
, et al
.
Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up
.
Ann Hematol
.
2018
;
97
(
3
):
443
-
451
.
18.
Bartels
S
,
Faisal
M
,
Büsche
G
,
Schlue
J
,
Kreipe
H
,
Lehmann
U
.
Fibrotic progression in polycythemia vera is associated with early concomitant driver-mutations besides JAK2
.
Leukemia
.
2018
;
32
(
2
):
556
-
558
.
19.
Grinfeld
J
,
Nangalia
J
,
Baxter
EJ
, et al
.
Classification and personalized prognosis in myeloproliferative neoplasms
.
N Engl J Med
.
2018
;
379
(
15
):
1416
-
1430
.
20.
Xie
M
,
Lu
C
,
Wang
J
, et al
.
Age-related mutations associated with clonal hematopoietic expansion and malignancies
.
Nat Med
.
2014
;
20
(
12
):
1472
-
1478
.
21.
McNally
RJ
,
Rowland
D
,
Roman
E
,
Cartwright
RA
.
Age and sex distributions of hematological malignancies in the U.K
.
Hematol Oncol
.
1997
;
15
(
4
):
173
-
189
.
22.
Steensma
DP
,
Bejar
R
,
Jaiswal
S
, et al
.
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
.
Blood
.
2015
;
126
(
1
):
9
-
16
.
23.
Stein
BL
,
Rademaker
A
,
Spivak
JL
,
Moliterno
AR
.
Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms
.
Thrombosis
.
2011
;
2011
:
874146
.
24.
Spivak
JL
.
Polycythemia vera and the emperor’s new clothes
.
Haematologica
.
2003
;
88
(
1
):
1
-
4
.
25.
Stein
BL
,
Saraf
S
,
Sobol
U
, et al
.
Age-related differences in disease characteristics and clinical outcomes in polycythemia vera
.
Leuk Lymphoma
.
2013
;
54
(
9
):
1989
-
1995
.
26.
Hultcrantz
M
,
Björkholm
M
,
Dickman
PW
, et al
.
Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study
.
Ann Intern Med
.
2018
;
168
(
5
):
317
-
325
.
27.
Plo
I
,
Nakatake
M
,
Malivert
L
, et al
.
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
.
Blood
.
2008
;
112
(
4
):
1402
-
1412
.
28.
Mora
B
,
Giorgino
T
,
Guglielmelli
P
, et al
.
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia
.
Leuk Res
.
2018
;
69
:
100
-
102
.
29.
Hidalgo López
JE
,
Carballo-Zarate
A
,
Verstovsek
S
, et al
.
Bone marrow findings in blast phase of polycythemia vera
.
Ann Hematol
.
2018
;
97
(
3
):
425
-
434
.
30.
Najean
Y
,
Arrago
JP
,
Rain
JD
,
Dresch
C
.
The “spent” phase of polycythaemia vera: hypersplenism in the absence of myelofibrosis
.
Br J Haematol
.
1984
;
56
(
1
):
163
-
170
.
31.
Wang
L
,
Swierczek
SI
,
Lanikova
L
, et al
.
The relationship of JAK2(V617F) and acquired UPD at chromosome 9p in polycythemia vera
.
Leukemia
.
2014
;
28
(
4
):
938
-
941
.
32.
Lamy
T
,
Devillers
A
,
Bernard
M
, et al
.
Inapparent polycythemia vera: an unrecognized diagnosis
.
Am J Med
.
1997
;
102
(
1
):
14
-
20
.
33.
Cassinat
B
,
Laguillier
C
,
Gardin
C
, et al
; PV-Nord Group.
Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?
Leukemia
.
2008
;
22
(
2
):
452
-
453
.
34.
Passamonti
F
,
Rumi
E
,
Caramella
M
, et al
.
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis
.
Blood
.
2008
;
111
(
7
):
3383
-
3387
.
35.
Passamonti
F
,
Giorgino
T
,
Mora
B
, et al
.
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
.
Leukemia
.
2017
;
31
(
12
):
2726
-
2731
.
36.
Kuter
DJ
,
Bain
B
,
Mufti
G
,
Bagg
A
,
Hasserjian
RP
.
Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres
.
Br J Haematol
.
2007
;
139
(
3
):
351
-
362
.
37.
Ellis
JT
,
Peterson
P
,
Geller
SA
,
Rappaport
H
.
Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies
.
Semin Hematol
.
1986
;
23
(
2
):
144
-
155
.
38.
Barraco
D
,
Cerquozzi
S
,
Hanson
CA
, et al
.
Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations
.
Blood Cancer J
.
2017
;
7
(
3
):
e538
.
39.
Berk
PD
,
Goldberg
JD
,
Silverstein
MN
, et al
.
Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy
.
N Engl J Med
.
1981
;
304
(
8
):
441
-
447
.
40.
Kiladjian
JJ
,
Chevret
S
,
Dosquet
C
,
Chomienne
C
,
Rain
JD
.
Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980
.
J Clin Oncol
.
2011
;
29
(
29
):
3907
-
3913
.
41.
Klampfl
T
,
Harutyunyan
A
,
Berg
T
, et al
.
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression
.
Blood
.
2011
;
118
(
1
):
167
-
176
.
42.
Thoennissen
NH
,
Krug
UO
,
Lee
DH
, et al
.
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms
.
Blood
.
2010
;
115
(
14
):
2882
-
2890
.
43.
Theocharides
A
,
Boissinot
M
,
Girodon
F
, et al
.
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation
.
Blood
.
2007
;
110
(
1
):
375
-
379
.
44.
Beer
PA
,
Delhommeau
F
,
LeCouédic
JP
, et al
.
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm
.
Blood
.
2010
;
115
(
14
):
2891
-
2900
.
45.
Mora
B
,
Giorgino
T
,
Guglielmelli
P
, et al
.
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
.
Haematologica
.
2018
;
103
(
9
):
e392
-
e394
.
46.
Taylor
KM
,
Shetta
M
,
Talpaz
M
, et al
.
Myeloproliferative disorders: usefulness of X-linked probes in diagnosis
.
Leukemia
.
1989
;
3
(
6
):
419
-
422
.
47.
Berlin
NI
.
Diagnosis and classification of the polycythemias
.
Semin Hematol
.
1975
;
12
(
4
):
339
-
351
.
48.
Berglund
S
,
Zettervall
O
.
Incidence of polycythemia vera in a defined population
.
Eur J Haematol
.
1992
;
48
(
1
):
20
-
26
.
49.
Wilkins
BS
,
Erber
WN
,
Bareford
D
, et al
.
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes
.
Blood
.
2008
;
111
(
1
):
60
-
70
.
50.
Silver
RT
,
Chow
W
,
Orazi
A
,
Arles
SP
,
Goldsmith
SJ
.
Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis
.
Blood
.
2013
;
122
(
11
):
1881
-
1886
.
51.
McMullin
MF
,
Harrison
CN
,
Ali
S
, et al
; BSH Committee.
A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline
.
Br J Haematol
.
2019
;
184
(
2
):
176
-
191
.
52.
Weber
FP
.
Polycythaemia, erythrocytosis and erythraemia
.
Q J Med
.
1908
;
2
:
85
-
134
.
53.
Conrad
ME
,
Crosby
WH
.
The natural history of iron deficiency induced by phlebotomy
.
Blood
.
1962
;
20
:
173
-
185
.
54.
Bessman
JD
.
Microcytic polycythemia. Frequency of nonthalassemic causes
.
JAMA
.
1977
;
238
(
22
):
2391
-
2392
.
55.
Emanuel
RM
,
Dueck
AC
,
Geyer
HL
, et al
.
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs [published correction appears in J Clin Oncol. 2012;30(36):4590]
.
J Clin Oncol
.
2012
;
30
(
33
):
4098
-
4103
.
56.
Scherber
RM
,
Kosiorek
HE
,
Senyak
Z
, et al
.
Comprehensively understanding fatigue in patients with myeloproliferative neoplasms
.
Cancer
.
2016
;
122
(
3
):
477
-
485
.
57.
Rector
WG
Jr
,
Fortuin
NJ
,
Conley
CL
.
Non-hematologic effects of chronic iron deficiency. A study of patients with polycythemia vera treated solely with venesections
.
Medicine (Baltimore)
.
1982
;
61
(
6
):
382
-
389
.
58.
Torgano
G
,
Mandelli
C
,
Massaro
P
, et al
.
Gastroduodenal lesions in polycythaemia vera: frequency and role of Helicobacter pylori
.
Br J Haematol
.
2002
;
117
(
1
):
198
-
202
.
59.
Mansier
O
,
Luque Paz
D
,
Ianotto
JC
, et al
.
Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study
.
Am J Hematol
.
2018
;
93
(
4
):
E84
-
E86
.
60.
Moliterno
AR
,
Williams
DM
,
Rogers
O
,
Isaacs
MA
,
Spivak
JL
.
Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens
.
Exp Hematol
.
2008
;
36
(
11
):
1480
-
1486
.
61.
Masarova
L
,
Bose
P
,
Daver
N
, et al
.
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis
.
Leuk Res
.
2017
;
59
:
110
-
116
.
62.
Guglielmelli
P
,
Barosi
G
,
Pieri
L
,
Antonioli
E
,
Bosi
A
,
Vannucchi
AM
.
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis
.
Haematologica
.
2009
;
94
(
1
):
144
-
146
.
63.
Tang
G
,
Hidalgo Lopez
JE
,
Wang
SA
, et al
.
Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
.
Haematologica
.
2017
;
102
(
9
):
1511
-
1518
.
64.
Sánchez-Luceros
A
,
Meschengieser
SS
,
Woods
AI
, et al
.
Acquired von Willebrand factor abnormalities in myeloproliferative disorders and other hematologic diseases: a retrospective analysis by a single institution
.
Haematologica
.
2002
;
87
(
3
):
264
-
270
.
65.
Tefferi
A
,
Vannucchi
AM
,
Barbui
T
.
Polycythemia vera treatment algorithm 2018
.
Blood Cancer J
.
2018
;
8
(
1
):
3
.
66.
Harrison
CN
,
Campbell
PJ
,
Buck
G
, et al
; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study.
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
.
N Engl J Med
.
2005
;
353
(
1
):
33
-
45
.
67.
Gisslinger
H
,
Gotic
M
,
Holowiecki
J
, et al
; ANAHYDRET Study Group.
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
.
Blood
.
2013
;
121
(
10
):
1720
-
1728
.
68.
Cortelazzo
S
,
Finazzi
G
,
Ruggeri
M
, et al
.
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
.
N Engl J Med
.
1995
;
332
(
17
):
1132
-
1136
.
69.
Alvarez-Larrán
A
,
Pereira
A
,
Cervantes
F
, et al
.
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
.
Blood
.
2012
;
119
(
6
):
1363
-
1369
.
70.
Marchioli
R
,
Finazzi
G
,
Landolfi
R
, et al
.
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
.
J Clin Oncol
.
2005
;
23
(
10
):
2224
-
2232
.
71.
Marchioli
R
,
Finazzi
G
,
Specchia
G
, et al
; CYTO-PV Collaborative Group.
Cardiovascular events and intensity of treatment in polycythemia vera
.
N Engl J Med
.
2013
;
368
(
1
):
22
-
33
.
72.
Pearson
TC
,
Wetherley-Mein
G
.
Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia
.
Lancet
.
1978
;
2
(
8102
):
1219
-
1222
.
73.
Barosi
G
,
Mesa
R
,
Finazzi
G
, et al
.
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
.
Blood
.
2013
;
121
(
23
):
4778
-
4781
.
74.
Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia
.
Ann Intern Med
.
1995
;
123
(
9
):
656
-
664
.
75.
Gangat
N
,
Wolanskyj
AP
,
Schwager
SM
,
Hanson
CA
,
Tefferi
A
.
Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera
.
Cancer
.
2009
;
115
(
24
):
5740
-
5745
.
76.
Kessler
CM
,
Klein
HG
,
Havlik
RJ
.
Uncontrolled thrombocytosis in chronic myeloproliferative disorders
.
Br J Haematol
.
1982
;
50
(
1
):
157
-
167
.
77.
Palandri
F
,
Catani
L
,
Testoni
N
, et al
.
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy
.
Am J Hematol
.
2009
;
84
(
4
):
215
-
220
.
78.
Passamonti
F
,
Rumi
E
,
Pietra
D
, et al
.
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
.
Leukemia
.
2010
;
24
(
9
):
1574
-
1579
.
79.
Alvarez-Larrán
A
,
Kerguelen
A
,
Hernández-Boluda
JC
, et al
; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN).
Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera
.
Br J Haematol
.
2016
;
172
(
5
):
786
-
793
.
80.
Antonioli
E
,
Carobbio
A
,
Pieri
L
, et al
.
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia
.
Haematologica
.
2010
;
95
(
8
):
1435
-
1438
.
81.
Jain
P
,
Verstovsek
S
,
Wang
W
, et al
.
DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia
.
Leuk Lymphoma
.
2016
;
57
(
8
):
1969
-
1973
.
82.
Verger
E
,
Rattarittamrong
E
,
Letort
G
,
Raffoux
E
,
Cassinat
B
,
Kiladjian
JJ
.
Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone
.
Leuk Lymphoma
.
2017
;
58
(
3
):
749
-
751
.
83.
Hernández-Boluda
JC
,
Pereira
A
,
Gómez
M
, et al
; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas.
The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis
.
Haematologica
.
2014
;
99
(
4
):
e55
-
e57
.
84.
Gowin
K
,
Coakley
M
,
Kosiorek
H
,
Mesa
R
.
Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis
.
Haematologica
.
2016
;
101
(
10
):
e405
-
e406
.
85.
Mesa
RA
,
Nagorney
DS
,
Schwager
S
,
Allred
J
,
Tefferi
A
.
Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic
.
Cancer
.
2006
;
107
(
2
):
361
-
370
.
86.
Dameshek
W
.
The case for phlebotomy in polycythemia vera
.
Blood
.
1968
;
32
(
3
):
488
-
491
.
87.
Berlin
NI
.
Louis R. Wasserman and the history of polycythemia vera
.
Mt Sinai J Med
.
1995
;
62
(
3
):
206
-
215
.
88.
Marchioli
R
,
Vannucchi
AM
,
Barbui
T
.
Treatment target in polycythemia vera
.
N Engl J Med
.
2013
;
368
(
16
):
1556
.
89.
Di Veroli
A
,
Buccisano
F
,
Andriani
A
, et al
.
Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: a retrospective analysis of 623 PTS With long follow-up
.
Leuk Res
.
2018
;
69
:
18
-
23
.
90.
Najean
Y
,
Rain
JD
.
Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years
.
Blood
.
1997
;
90
(
9
):
3370
-
3377
.
91.
Fruchtman
SM
,
Mack
K
,
Kaplan
ME
,
Peterson
P
,
Berk
PD
,
Wasserman
LR
.
From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera
.
Semin Hematol
.
1997
;
34
(
1
):
17
-
23
.
92.
Wong
TN
,
Miller
CA
,
Jotte
MRM
, et al
.
Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential
.
Nat Commun
.
2018
;
9
(
1
):
455
.
93.
Best
PJ
,
Petitt
RM
.
Multiple skin cancers associated with hydroxyurea therapy
.
Mayo Clin Proc
.
1998
;
73
(
10
):
961
-
963
.
94.
Finazzi
G
,
Ruggeri
M
,
Rodeghiero
F
,
Barbui
T
.
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial
.
Br J Haematol
.
2000
;
110
(
3
):
577
-
583
.
95.
Najean
Y
,
Rain
JD
; The French Polycythemia Study Group.
Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age
.
Blood
.
1997
;
89
(
7
):
2319
-
2327
.
96.
Gottifredi
V
,
Shieh
S
,
Taya
Y
,
Prives
C
.
p53 accumulates but is functionally impaired when DNA synthesis is blocked
.
Proc Natl Acad Sci USA
.
2001
;
98
(
3
):
1036
-
1041
.
97.
Morison
WL
,
Nesbitt
JA
III
.
Oral psoralen photochemotherapy (PUVA) for pruritus associated with polycythemia vera and myelofibrosis
.
Am J Hematol
.
1993
;
42
(
4
):
409
-
410
.
98.
Michiels
JJ
,
Berneman
Z
,
Schroyens
W
, et al
.
Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia
.
Platelets
.
2006
;
17
(
8
):
528
-
544
.
99.
Teofili
L
,
Valentini
CG
,
Rossi
E
,
De Stefano
V
.
Indications and use of therapeutic phlebotomy in polycythemia vera: which role for erythrocytapheresis?
Leukemia
.
2019
;
33
(
1
):
279
-
281
.
100.
Finch
S
,
Haskins
D
,
Finch
CA
.
Iron metabolism; hematopoiesis following phlebotomy; iron as a limiting factor
.
J Clin Invest
.
1950
;
29
(
8
):
1078
-
1086
.
101.
Messinezy
M
,
Pearson
TC
.
Incidence of myelofibrosis following treatment of primary polycythaemia by venesection [letter; comment]
.
Br J Haematol
.
1995
;
89
(
1
):
228
-
230
.
102.
Barbui
T
,
Carobbio
A
,
Ghirardi
A
,
Masciulli
A
,
Rambaldi
A
,
Vannucchi
AM
.
No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials
.
Haematologica
.
2017
;
102
(
6
):
e219
-
e221
.
103.
Marchioli
R
,
Finazzi
G
,
Specchia
G
, et al
; CYTO-PV Collaborative Group.
Cardiovascular events and intensity of treatment in polycythemia vera
.
N Engl J Med
.
2013
;
368
(
1
):
22
-
33
.
104.
Pearson
TC
,
Guthrie
DL
,
Simpson
J
, et al
.
Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology
.
Br J Haematol
.
1995
;
89
(
4
):
748
-
756
.
105.
Smalberg
JH
,
Arends
LR
,
Valla
DC
,
Kiladjian
JJ
,
Janssen
HL
,
Leebeek
FW
.
Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis
.
Blood
.
2012
;
120
(
25
):
4921
-
4928
.
106.
Wells
RE
Jr
,
Merrill
EW
.
Influence of flow properties of blood upon viscosity-hematocrit relationships
.
J Clin Invest
.
1962
;
41
(
8
):
1591
-
1598
.
107.
De Stefano
V
,
Rossi
E
,
Carobbio
A
, et al
.
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
.
Blood Cancer J
.
2018
;
8
(
11
):
112
.
108.
Hytten
F
.
Blood volume changes in normal pregnancy
.
Clin Haematol
.
1985
;
14
(
3
):
601
-
612
.
109.
Milman
N
,
Byg
KE
,
Agger
AO
.
Hemoglobin and erythrocyte indices during normal pregnancy and postpartum in 206 women with and without iron supplementation
.
Acta Obstet Gynecol Scand
.
2000
;
79
(
2
):
89
-
98
.
110.
Cantor
AG
,
Bougatsos
C
,
Dana
T
,
Blazina
I
,
McDonagh
M
.
Routine iron supplementation and screening for iron deficiency anemia in pregnancy: a systematic review for the U.S. Preventive Services Task Force
.
Ann Intern Med
.
2015
;
162
(
8
):
566
-
576
.
111.
Spivak
JL
.
Thrombocytosis, pregnancy, and regression toward the mean
.
Blood
.
2007
;
110
(
2
):
472
-
473
.
112.
McMullin
MFF
,
Mead
AJ
,
Ali
S
, et al
; British Society for Haematology Guideline.
A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline
.
Br J Haematol
.
2019
;
184
(
2
):
161
-
175
.
113.
Landolfi
R
,
Marchioli
R
,
Kutti
J
, et al
; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators.
Efficacy and safety of low-dose aspirin in polycythemia vera
.
N Engl J Med
.
2004
;
350
(
2
):
114
-
124
.
114.
Squizzato
A
,
Romualdi
E
,
Middeldorp
S
.
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia [updated in Cochrane Database Syst Rev. 2013;(4):CD006503]
.
Cochrane Database Syst Rev
.
2008
;(
2
):
CD006503
.
115.
Patrono
C
,
Rocca
B
,
De Stefano
V
.
Platelet activation and inhibition in polycythemia vera and essential thrombocythemia
.
Blood
.
2013
;
121
(
10
):
1701
-
1711
.
116.
Baigent
C
,
Blackwell
L
,
Collins
R
, et al
; Antithrombotic Trialists’ (ATT) Collaboration.
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
.
Lancet
.
2009
;
373
(
9678
):
1849
-
1860
.
117.
Valgimigli
M
.
The remarkable story of a wonder drug, which now comes to an end in the primary prevention setting: say bye-bye to aspirin!
.
Eur Heart J
.
2019
;
40
(
7
):
618
-
620
.
118.
Bibbins-Domingo
K
; U.S. Preventive Services Task Force.
Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement
.
Ann Intern Med
.
2016
;
164
(
12
):
836
-
845
.
119.
Verstovsek
S
.
Therapeutic potential of JAK2 inhibitors
.
Hematology Am Soc Hematol Educ Program
.
2009
;
2009
:
636
-
642
.
120.
Mullally
A
,
Bruedigam
C
,
Poveromo
L
, et al
.
Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera
.
Blood
.
2013
;
121
(
18
):
3692
-
3702
.
121.
Wang
X
,
Ye
F
,
Tripodi
J
, et al
.
JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis
.
Blood
.
2014
;
124
(
19
):
2987
-
2995
.
122.
Porpaczy
E
,
Tripolt
S
,
Hoelbl-Kovacic
A
, et al
.
Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
.
Blood
.
2018
;
132
(
7
):
694
-
706
.
123.
Masarova
L
,
Patel
KP
,
Newberry
KJ
, et al
.
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial
.
Lancet Haematol
.
2017
;
4
(
4
):
e165
-
e175
.
124.
Verstovsek
S
,
Mesa
RA
,
Gotlib
J
, et al
.
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
.
N Engl J Med
.
2012
;
366
(
9
):
799
-
807
.
125.
Vannucchi
AM
,
Kiladjian
JJ
,
Griesshammer
M
, et al
.
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
.
N Engl J Med
.
2015
;
372
(
5
):
426
-
435
.
126.
Passamonti
F
,
Griesshammer
M
,
Palandri
F
, et al
.
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
.
Lancet Oncol
.
2017
;
18
(
1
):
88
-
99
.
127.
Kiladjian
JJ
,
Cassinat
B
,
Chevret
S
, et al
.
Pegylated interferon-alfa-2a induces complete hematological and molecular responses with low toxicity in polycythemia vera
.
Blood
.
2008
;
112
(
8
):
3065
-
3072
.
128.
Quintás-Cardama
A
,
Abdel-Wahab
O
,
Manshouri
T
, et al
.
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a
.
Blood
.
2013
;
122
(
6
):
893
-
901
.
129.
Silver
RT
,
Kiladjian
JJ
,
Hasselbalch
HC
.
Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
.
Expert Rev Hematol
.
2013
;
6
(
1
):
49
-
58
.
130.
Preudhomme
C
,
Guilhot
J
,
Nicolini
FE
, et al
; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC).
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia
.
N Engl J Med
.
2010
;
363
(
26
):
2511
-
2521
.
131.
Masarova
L
,
Yin
CC
,
Cortes
JE
, et al
.
Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
.
Exp Hematol Oncol
.
2017
;
6
:
30
.
132.
Essers
MA
,
Offner
S
,
Blanco-Bose
WE
, et al
.
IFNalpha activates dormant haematopoietic stem cells in vivo
.
Nature
.
2009
;
458
(
7240
):
904
-
908
.
133.
Grunwald
MR
,
Spivak
JL
.
Ruxolitinib enhances platelet production in patients with thrombocytopenic myelofibrosis
.
J Clin Oncol
.
2016
;
34
(
5
):
e38
-
e40
.
134.
Lussana
F
,
Cattaneo
M
,
Rambaldi
A
,
Squizzato
A
.
Ruxolitinib-associated infections: a systematic review and meta-analysis
.
Am J Hematol
.
2018
;
93
(
3
):
339
-
347
.
135.
Heine
A
,
Brossart
P
,
Wolf
D
.
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
Blood
.
2013
;
122
(
23
):
3843
-
3844
.
136.
Mesa
RA
,
Steensma
DP
,
Pardanani
A
, et al
.
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia
.
Blood
.
2003
;
101
(
7
):
2534
-
2541
.
137.
Masarova
L
,
Verstovsek
S
,
Hidalgo-Lopez
JE
, et al
.
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
.
Blood
.
2018
;
132
(
16
):
1664
-
1674
.
138.
Odenike
OM
,
Larson
RA
,
Gajria
D
, et al
.
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia
.
Invest New Drugs
.
2008
;
26
(
3
):
233
-
239
.
You do not currently have access to this content.